{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["37(3)"],"submitter":["Sbarigia U"],"funding":["Janssen Scientific Affairs, LLC"],"pubmed_abstract":["<h4>Introduction</h4>This study aimed to characterize chronic hepatitis B (CHB)-infected patients and estimate the association between nucleos(t)ide analogue (NA) persistence and economic outcomes using data from the Veterans Health Administration (VHA) database.<h4>Methods</h4>Patients (at least 18 years of age) with two or more claims for CHB and at least one pharmacy claim for NA were identified using VHA data from 1 April 2013 to 31 March 2018. The index date was the first NA prescription fill date during 1 October 2014 to 31 March 2017. Persistence and non-persistence to NA treatment were assessed during the first 2 years post index date. Non-persistence was defined as at least one failure to refill medication within 30 days from the run-out date. Generalized linear models were used t"],"journal":["Advances in therapy"],"pagination":["1156-1172"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7089729"],"repository":["biostudies-literature"],"pubmed_title":["Evaluating the Effect of Standard of Care Treatment on Burden of Chronic Hepatitis B: A Retrospective Analysis of the United States Veterans Population."],"pmcid":["PMC7089729"],"pubmed_authors":["Katz EG","Colasurdo J","Xie L","Sah J","Sylvester S","Sbarigia U","Kariburyo F"],"additional_accession":[]},"is_claimable":false,"name":"Evaluating the Effect of Standard of Care Treatment on Burden of Chronic Hepatitis B: A Retrospective Analysis of the United States Veterans Population.","description":"<h4>Introduction</h4>This study aimed to characterize chronic hepatitis B (CHB)-infected patients and estimate the association between nucleos(t)ide analogue (NA) persistence and economic outcomes using data from the Veterans Health Administration (VHA) database.<h4>Methods</h4>Patients (at least 18 years of age) with two or more claims for CHB and at least one pharmacy claim for NA were identified using VHA data from 1 April 2013 to 31 March 2018. The index date was the first NA prescription fill date during 1 October 2014 to 31 March 2017. Persistence and non-persistence to NA treatment were assessed during the first 2 years post index date. Non-persistence was defined as at least one failure to refill medication within 30 days from the run-out date. Generalized linear models were used t","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Mar","modification":"2025-04-18T18:39:35.955Z","creation":"2020-05-22T14:24:41Z"},"accession":"S-EPMC7089729","cross_references":{"pubmed":["32009232"],"doi":["10.1007/s12325-020-01240-1"]}}